Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

M. Jotte, Robert; Cappuzzo, Federico; Vynnychenko, Ihor; Stroyakovskiy, Daniil; Rodríguez‐Abreu, Delvys; Hussein, Maen; A. Soo, Ross; Jacob Conter, Henry; Kozuki, Toshiyuki; Huang, Kuan-Chieh; Graupner, Vilma; W. Sun, Shawn; Hoang, Tien; Jessop, Helen; L. McCleland, Mark; Ballinger, Marcus; Sandler, Alan; A. Socinski, Mark

doi:10.1016/j.jtho.2020.03.028

Public

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Published in Journal of Thoracic Oncology • Apr 14, 2020

Authors:

Robert M. Jotte

Federico Cappuzzo

Ihor Vynnychenko

Abstract

INTRODUCTION: Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated atezolizumab with platinum-based chemotherapy in stage IV ...

Subject

Atezolizumab

Medicine

Carboplatin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!